Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors

Hideki Yamaguchi,1 Miho Takanashi,1,2 Nachi Yoshida,1,3 Yuumi Ito,1,2 Reiko Kamata,1 Kiyoko Fukami,2 Kazuyoshi Yanagihara4 and Ryuichi Sakai1

1Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo; 2Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo; 3Laboratory of Cellular Regulation and Biomedical Science, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan; 4Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo

Key words
C-Met, c-src, neoplasm metastasis, saracatinib, stomach neoplasms

Correspondence
Ryuichi Sakai, Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Tel +81-3-3547-5247; Fax +81-3-3542-8170; E-mail: rsakai@ncc.go.jp

Funding information
National Cancer Center Research and Development Fund (23-A-9). Japan Society for the Promotion of Science. Ministry of Education, Culture, Sports, Science and Technology of Japan. Ministry of Health, Labour and Welfare of Japan. The Mochida Memorial Foundation for Medical and Pharmaceutical Research. The Sagawa Foundation for Promotion of Cancer Research.

Received November 25, 2013; Revised February 18, 2014; Accepted February 20, 2014

Cancer Sci 105 (2014) 528–536
doi: 10.1111/cas.12387

Gastric adenocarcinomas are histologically classified into two major subtypes according to the Lauren classification: intestinal and diffuse.1 Diffuse-type gastric carcinoma (DGC) is also called poorly differentiated gastric carcinoma and often exhibits aggressive progression.2–4 Scirrhous gastric carcinoma (SGC) is a subtype of DGC characterized by rapid infiltrative growth accompanied by massive stromal fibrosis and frequent metastasis to lymph nodes and the peritoneum.5 These aggressive characteristics contribute to the extremely poor prognosis of patients with SGC.6–7 Several genetic alterations have been implicated in DGC, including gene amplification of c-met and FGFR2/k-sam.8–10

The oncogene c-met encodes Met receptor type tyrosine kinase whose ligand is hepatocyte growth factor (HGF). Met signaling regulates multiple aspects of cancer malignancies, including cell migration and invasion, cell proliferation and survival, and angiogenesis.11 Amplification and germline and somatic mutations of c-met have been found in a wide spectrum of human cancers.12 Therefore, Met is considered to be a promising therapeutic target, and dozens of Met inhibitors are being evaluated in clinical trials.12–14 Met amplification is correlated with poor prognosis in gastric cancer patients.10,15,16

FGFR2/k-sam encodes fibroblast growth factor receptor (FGFR) type 2, a member of the FGFR receptor tyrosine kinase family, and its mutation and amplification have been detected and correlated with poor prognosis in several human cancers, including gastric cancers.17 Similar to Met, FGFR2 signaling regulates many cellular functions that contribute to cancer progression, including cell proliferation, survival and migration.17 Accordingly, FGFR inhibitors are being tested in clinical trials.18

Several studies have revealed that gastric cancer cell lines exhibiting Met amplification are sensitive to Met inhibitors.16,19–24 Likewise, FGFR2 inhibitors have been shown to block cell growth and peritoneal dissemination of SGC cells with FGFR gene amplification.25–27 However, amplification of c-met and FGFR2 occurs only in a limited fraction: approximately 2–20% and 10% of all gastric cancers, respectively.10,15,19,28–30 Therefore, a molecular target remains to be determined for the treatment of the fraction of DGC with neither c-met nor FGFR2 amplification/activating mutation.
In this study, we performed a detailed analysis of tyrosine-phosphorylated proteins in a panel of gastric cancer cell lines to identify signaling pathways or molecules that could be molecular targets for DGC chemotherapy.

Materials and Methods

Cell culture. The human gastric cancer cell lines used, that is, HSC-39, HSC-43, HSC-59, HSC-60, HSC-64, HSC-44PE, 58As9, 58As1, 44As3 and 44As3Luc, have been described previously. (31–34) MKN1, MKN7, MKN74, NUGC-4, KATO-III, MKN45 and IM95 were obtained from the Health Science Research Resources Bank. AGS, NCI-N87 and SNU-5 were obtained from the American Type Culture Collection (ATCC). GCIY, ECC12, AZ521 and KE-97 were provided by the RIKEN Bio-Resource Center through the National Bio-Resource Project of the MEXT, Japan. These cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 10 units/mL of penicillin and 10 μg/mL of streptomycin at 37°C in a humidified atmosphere containing 5% CO2.

Reagents and antibodies. Antibodies, including phospho-specific antibodies, against Met, Src, ERK, Akt, FRS2α and Stat3 were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against Met and FRS2 were also purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against FGFR2 and phospho-FGFR1-4 were purchased from R&D Systems (Minneapolis, MN, USA). Anti-phosphotyrosine (4G10) antibody was obtained from Merck Millipore (Billerica, MA, USA). Anti-phosphotyrosine antibody 4G10 (Fig. 1a). The amount of phosphotyrosine-containing proteins mainly distributed from 37 to 250 kDa was greatly elevated in several DGC cell lines, including MKN45, KATO-III, 58As1, 58As9 and SNU-5. Other cell lines exhibited moderate or only a modest level of tyrosine-phosphorylated proteins. Notably, the band pattern of phosphotyrosine-containing proteins in DGC cell lines, which apparently varied among lines, was significantly distinct from those in differentiated gastric cancer cells. These observations indicate that DGC display specific activation of some intracellular signaling pathways involving tyrosine phosphorylation.

Met is overexpressed and highly phosphorylated in diffuse-type gastric carcinoma cells. To identify molecules that account for increased tyrosine phosphorylation in DGC cell lines, phosphotyrosine proteins were affinity purified from 58As9 cells and subjected to mass spectrometry. As a result, the most prominent band at approximately 140 kDa was identified as Met, a receptor tyrosine kinase for HGF ligand (Fig. S1). Many of the DGC cell lines showed significant increases in both expression and phosphorylation of Met compared with those in other gastric cancer cell lines (Fig. 1a,b). Notably, MKN45, 58As1, 58As9 and SNU-5 cells that showed the highest expression of Met inhibitors (PHA-665752, JNJ-38877605 and PF-2341066 [crizotinib]) on the growth of DGC cell lines were determined (Fig. 1c). These Met inhibitors effectively suppressed the growth of MKN45, 58As1, 58As9 and SNU-5 cells that showed the highest expression of Met. By contrast, Met inhibitors had no effect on the growth of other cell lines. These results are consistent with those of other studies that have used similar but different sets of gastric cancer cell lines and Met inhibitors. (20,23,24) Met inhibitor-insensitive 44As3 and Met inhibitor-sensitive 58As9 cells were chosen for further analyses, as both are highly metastatic in a mouse peritoneal dissemination model. (33)

The IC50 values of Met inhibitors in 44As3 and 58As9 cells were approximately 1500 and 19 nM for PHA-665752, >10 000 and 6.9 nM for JNJ-38877605, and 2600 and 21 nM...
for PF-2341066, respectively (Fig. S2a). Met inhibitors significantly blocked phosphorylation of Met in both 44As3 and 58As9 cells (Fig. 2a). Nonetheless, overall protein tyrosine phosphorylation and phosphorylation of ERK, Akt and Stat3 were significantly decreased only in 58As9 cells (Fig. 2a,b). Interestingly, Src phosphorylation was rather increased in 58As9 cells upon Met inhibition, whereas it was unchanged in 44As3 cells (Fig. 2a). Similar results were obtained with PF-2341066 (Fig. S2b). Met inhibitor treatment also induced marked changes in cell morphology in 58As9 but not in 44As3 cells: rounded morphology was converted to flattened and adherent phenotypes (Fig. 2c). Serum starvation reduced and following HGF stimulation increased Met phosphorylation in 44As3 cells, whereas Met was constitutively phosphorylated in 58As9 cells (Fig. 2d). Consequently, growth of 44As3 but not of 58As9 cells was sensitive to serum starvation (Fig. 2e). These results indicate that overexpressed Met proteins confer the capability for serum-independent growth to 58As9 cells via...

**Fig. 1.** Diffuse-type gastric carcinoma (DGC) cell lines with robust overexpression of Met are sensitive to Met inhibitors. (a) DGC and other gastric carcinoma cell lines were subjected to immunoblot analysis with anti-phosphotyrosine (4G10) and anti-Met antibodies. (b) The relative levels of phospho-Met and total Met were quantified from immunoblot data as described in the Materials and Methods. Bars, SD (n = 4 for phospho-Met and 3 for total Met). *P < 0.01, by Student’s t-test. (c) DGC cell lines were treated with 300 nM of Met inhibitors for 4 days, and cell viability was assessed. Bars, SD (n = 4). *P < 0.0001 versus other cell lines, by ANOVA with Tukey’s test.
activation of downstream signaling pathways, and, therefore, that 58As9 cells are susceptible to Met inhibitors. Next, the effect of Met inhibition on peritoneal dissemination of 44As3 and 58As9 cells was examined. Met inhibition remarkably reduced the formation of ascites and peritoneal dissemination in mice injected with 58As9 cells (Fig. 2f,g; Table 1). By contrast, Met inhibition had minimal effects on peritoneal dissemination of 44As3 cells; only a modest decrease in ascites formation was observed (Table 1). Taken together, Met inhibition seems to be extraordinarily effective against a portion of DGC that express high levels of Met proteins, although it is ineffective against other DGC.

Src inhibitor blocks growth of Met/fibroblast growth factor receptor-independent diffuse-type gastric carcinoma cell lines. The effects of several inhibitors targeted to signaling molecules other than Met were then examined. PD-173074, a pan-FGFR inhibitor, treatment strongly inhibited the growth of KATO-III and HSC-43 cells also showed robust overexpression of FGFR2α, which is consistent with k-sam amplification in those cell lines. Taken together, phosphorylation of FRS2α and overexpression of FGFR2α seem to be correlated with sensitivity to FGFR inhibition.

Because Met inhibitor treatment upregulated Src phosphorylation in 58As9 cells, we next tested the effect of the Src inhibitor saracatinib. Treatment with saracatinib significantly blocked the growth of several DGC cell lines, including NUGC-4, KATO-III, HSC-59, HSC-44PE, 44As3, HSC-60, GCiY and KE-97, but it had no effect on Met-dependent cell lines (Fig. 3a). These cell lines, with the exception of KATO-III, also lacked sensitivity to PD-173074. We also tested whether the combination of Met inhibitor and saracatinib has a synergistic effect on the proliferation of 58As9 cells. However, simultaneous addition of the both inhibitors had a minimal effect (Fig. S3). These observations clearly suggest that DGC have different, and nearly mutually exclusive, sensitivities to Met, FGFR and Src inhibitors.

Table 1. Effect of Met inhibition on ascites formation and dissemination of 44As3 and 58As9 cells

| Cell line | Treatment | Ascites | Omentum | Mesentry | Diaphragm | Liver |
|-----------|-----------|---------|---------|----------|-----------|-------|
| 44As3     | DMSO      | 6/11    | 11/11   | 11/11    | 5/11      | 5/11  |
|           | PHA       | 3/13    | 12/13   | 12/13    | 4/13      | 6/13  |
| 58As9     | DMSO      | 8/10    | 8/10    | 8/10     | 8/10      | 8/10  |
|           | PHA       | 0/10    | 6/10    | 1/10     | 0/10      | 0/10  |

| Number of mice bearing ascites or tumors at the indicated site per total number of mice bearing tumors. |
Immunoblot analysis showed that Src is equally expressed in all gastric cancer cell lines tested, and its phosphorylation also occurred in several DGC and other cell lines (Fig. 3b). Notably, however, the amount of phosphorylated Src was inversely correlated with that of phosphorylated Met in some DGC cell lines: cell lines with Met overexpression (MKN45, 58As1, 58As9 and SNU-5) have lower amounts of phosphorylated Src, whereas those with low expression of Met (NUGC-4, HSC-59 and HSC-60) have relatively high amounts of phosphorylated Src. As expected, saracatinib, but not Met and FGFR inhibitors, decreased overall tyrosine phosphorylation and ERK and Akt phosphorylation in saracatinib-responsive cell lines GCIY and HSC-60 (Fig. S4). Similarly, Met inhibitors, but not saracatinib or PD-173074, blocked overall tyrosine phosphorylation, as well as ERK, and Akt phosphorylation in MKN45 and 58As1. In HSC-39 and KATO-III cells, FGFR inhibition significantly suppressed phosphorylation of these signaling molecules.

Fig. 4. Saracatinib impairs peritoneal dissemination of 44As3 cells. (a) Viability of 44As3 and 58As9 cells treated with various concentrations of saracatinib for 4 days. (b, c) Cells were treated with saracatinib for 2 h and subjected to immunoblot analyses with indicated antibodies. (d) 44As3Luc and 58As9 cells were intraperitoneally injected into nude mice and DMSO (vehicle) or saracatinib was administered. Representative macroscopic views of mesentery tumor nodules are shown. (e) The number of mesentery tumor nodules. Bars, SEM (n = 16 for DMSO and 18 for saracatinib in 44As3Luc, n = 8 for DMSO and 7 for saracatinib in 58As9). *P < 0.001; and **P < 0.0001 by the Mann–Whitney test. (f) Representative images of mice obtained via in vivo imaging. (g) Quantitative analysis of luminescence photon counts. Bars, SD (n = 8 for DMSO and 9 for saracatinib). *P < 0.05; and **P < 0.0005 by the Mann–Whitney test. (h) Omental tumor weight in mice inoculated with 44As3Luc cells. Bars, SEM (n = 10 for DMSO and 9 for saracatinib). P = 0.3451 by the Mann–Whitney test.
Saracatinib impairs peritoneal dissemination of Met/fibroblast growth factor receptor-independent scirrhous gastric carcinoma cells. The IC50 values of saracatinib for the cell growth of 44As3 and 58As9 cells were 8.2 and 30 μM, respectively (Fig. 4a). Saracatinib treatment significantly decreased overall protein tyrosine phosphorylation in 44As3 but not in 58As9 cells (Fig. 4b). Interestingly, saracatinib did not affect the phosphorylation of Met, ERK and Akt (Fig. 4c). Saracatinib administration reduced the incidence of ascites formation and tumor dissemination to diaphragm and liver in 44As3 cells expressing luciferase (44As3Luc; Table 2). Although the incidence of dissemination to mesentery was not affected much by saracatinib, a marked reduction in the number of mesentery nodules was observed (Fig. 4d,e). In vivo imaging analysis confirmed that saracatinib treatment significantly reduces the growth and dissemination of 44As3Luc cells (Fig. 4f,g). In contrast, neither the incidence of omental metastasis nor the growth of omental tumors was affected by saracatinib treatment (Table 2 and Fig. 4h). Although saracatinib tended to suppress the formation of ascites and peritoneal dissemination by 58As9 cells, the effects were more moderate (Table 2 and Fig. 4d,e). These data indicate that saracatinib can suppress peritoneal dissemination of SGC cells that are insensitive to Met and FGFR inhibitors.

Discussion

This study showed that significant increases and changes in protein tyrosine phosphorylation occur in DGC cell lines. In particular, several cell lines showed remarkable increases in the levels of protein tyrosine phosphorylation mainly due to Met overexpression. Although Met was overexpressed and phosphorylated in a large portion of DGC cell lines, only a subset of cell lines with remarkable amounts of Met protein through gene amplification was sensitive to Met inhibitors. One such cell line, 58As9, exhibited constitutive activation of Met and resistance to serum starvation. These results are consistent with those of previous studies showing that genetic alteration of Met drives addiction to Met activity and predicts effective treatment outcome. (12,14,19,24,37)

Two previous studies have reported that Met inhibitors block peritoneal dissemination of MKN45 poorly differentiated gastric adenocarcinoma cells. (16,21) The present study is the first to show that Met inhibition also markedly reduces peritoneal dissemination of 58As9 SGC cells. Importantly, Met inhibition had little effect on dissemination of 44As3 SGC cells that have moderate levels of Met expression and phosphorylation. Likewise, FGFR inhibition had growth-inhibitory effects only in cell lines with a high FGFR or FRS2 activation status. Therefore, the activation status of the receptor signaling pathway may need to be considered in the clinical use of these molecular targeted drugs. We demonstrated that the amount of Met and FRS2 phosphorylation are closely correlated with sensitivity to Met and FGFR2 inhibitors, respectively. At least in the case of Met, immunohistochemical studies have demonstrated that Met is expressed and phosphorylated in human DGC with high Met gene copy number. (15,37) Thus, our results imply that the phosphorylation status of Met and FRS2 may be a good marker for predicting the therapeutic efficacy of Met and FGFR inhibitors.

To our knowledge, this study is the first to show that saracatinib, an Src inhibitor, suppresses peritoneal dissemination of SGC cells. More importantly, saracatinib reduced cell growth of DGC that are insensitive to both Met and FGFR inhibitors. We also found that sensitivities to Met, FGFR and Src inhibitors are almost mutually exclusive in DGC cell lines. Similar results regarding different sensitivities to Met and Src inhibitors in vitro have been reported in a different set of gastric carcinoma cell lines. (23) Our data show that SGC cell lines lacking amplification of Met and FGFR but displaying relatively high levels of Src phosphorylation tend to be responsive to saracatinib. Immunohistochemical study has shown that DGC cells display activation of Src that increases with the depth of invasion and correlates with the progression of DGC. (38) Thus, the activation status of Src may predict a good outcome for anti-Src therapy in DGC. Saracatinib treatment also effectively suppressed the growth of MKN74 and IM95 intestinal-type gastric carcinoma cells with high levels of Src phosphorylation (Figs S5 and 3b). Therefore, Src inhibitors may also be applicable to intestinal-type gastric carcinomas.

Administration of saracatinib did not affect the growth of omental tumors in mice inoculated with 44As3 cells, while it effectively blocked the formation of mesentery nodules. It is reported that the omentum is the first implantation site for malignant cells in peritoneal dissemination. (39) Therefore, saracatinib may mainly inhibit secondary spread of SGC cells from omental tumors. Alternatively, saracatinib may inhibit cell functions that are more important for colonization in mesenterium than in omentum. Src is a well-established regulator of cell migration and invasion, contributing to metastatic spread of malignant tumors. (40) This raises the possibility that saracatinib targets phosphoproteins involved in cell migration and invasion to exert such inhibitory effects on peritoneal dissemination of SGC cells.

In summary, our results demonstrate that Met and FGFR inhibitors are effective in subsets of DGC but not in other DGC. We found that the Src inhibitor saracatinib blocks cell growth and peritoneal dissemination of SGC cells that are insensitive to both Met and FGFR inhibitors. These results may provide a novel approach for molecular targeted therapy in DGC patients.

Acknowledgments

We thank Emi Saito for technical assistance. This work was supported by the National Cancer Center Research and Development Fund

Table 2. Effect of saracatinib on ascites formation and dissemination of 44As3Luc and 58As9 cells

| Cell line | Treatment | Ascites | Metastasis |
|-----------|-----------|---------|------------|
|           |           |         | Omentum | Mesentery | Diaphragm | Liver |
| 44As3Luc  | DMSO      | 14/16   | 14/16   | 16/16     | 4/16      | 9/16   |
|           | Saracatinib | 3/18    | 16/18   | 15/18     | 0/18      | 4/18   |
| 58As9     | DMSO      | 8/8     | 8/8     | 8/8       | 6/8       | 5/7    |
|           | Saracatinib | 3/7     | 7/7     | 7/7       | 5/7       | 5/7    |

Number of mice bearing ascites or tumors at the indicated site per total number of mice bearing tumors.
References

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49.

2. Inawarth N, Furukawa Y, Hasegawa S et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genomewide cDNA microarray. Oncogene 2004; 23: 6830–44.

3. Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1: 31–50.

4. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. J Gastroenterol 2002; 37 (Suppl. 13): 39–44.

5. Yashiro M, Hirakawa K. Cancer-stromal interactions in spheroid gastric carcinoma. Cancer Microenviron 2010; 3: 127–35.

6. Ikuguchi M, Miyake T, Matsunaga T et al. Recent results of therapy for spheroid gastric cancer. Surg Today 2009; 39: 290–4.

7. Otasuyi K, Kuriyama A, Okamoto K et al. Outcome of surgical treatment for patients with spheroid carcinoma of the stomach. Am J Surg Pathol 2004; 28(10): 327–32.

8. Hattori Y, Itoh H, Uchino S et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996; 2: 1373–81.

9. Hattori Y, Odagiri H, Nakatani H et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor gene family. Proc Natl Acad Sci USA 1990; 87: 5983–7.

10. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent gains, losses, and amplifications of K-sam, an amplified gene in stom- ach cancer. Jpn J Cancer Res 1991; 82: 227–32.

11. Trasolini L, Bertotti A, Comoglio PM. MET signalling: principles and func- tions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–48.

12. Comoglio PM, Giordano S, Trasolini L. Drug development of MET inhibitors: targeting oncogene addiction and epedebase. Nat Rev Drug Discov 2008; 7: 504–16.

13. Cecci F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46: 1260–70.

14. Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opinion Investig Drugs 2011; 20: 1223–41.

15. Lee J, Seo JW, Jun HJ et al. Impact of MET amplification on gastric cancer metastasis and development of new therapies. World J Surg Oncol 2011; 9: 144.

16. Yashiro M, Shintou O, Nakamura K et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on spheroid gastric carcinoma. Int J Cancer 2010; 126: 1004–16.

17. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluores- cence in situ hybridization. Lab Invest 1996; 78: 1143–53.

18. Persing M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosom Cancer 1998; 23: 307–16.

19. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991; 51: 381–6.

20. Yanagihara K, Takagihara M, Takeshita F et al. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res 2006; 66: 7532–9.

21. Yanagihara K, Takagihara M, Tanaka H et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005; 96: 323–32.

22. Yanagihara K, Tanaka H, Takagihara M et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metas- tase spontaneously in nude mice. Cancer Sci 2004; 95: 575–82.

23. Yanagihara K, Yoshida S, Murai E et al. Phosphomonoesterase 3-kinase signalling pathway mediated by p110alpha regulates invadopodia formation. J Cell Biol 2011; 193: 1275–88.

24. Ueda T, Sasaki H, Kuwahara Y et al. Deletion of the carboxy-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 1999; 59: 6808–6.

25. Catanecci DV, Henderson L, Xiao SY et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance recurrence. Cancer Discov 2011; 1: 573–9.

26. Huminar B, Fukuwazawa R, Blair V et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007; 67: 2480–9.

27. Hagiwara A, Takahashi T, Sawai K et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 1993; 53: 687–92.

28. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223: 14–26.

Medical and Pharmaceutical Research and The Sagawa Foundation for Promotion of Cancer Research.

Disclosure Statement

The authors have no conflict of interest.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. Purification and identification of tyrosine-phosphorylated proteins in 58A9 cells.

Fig. S2. Effects of Met inhibitors on cell growth and signaling in 44A3x and 58A9 cells.

Fig. S3. Effect of simultaneous addition of Met and Src inhibitors on proliferation of 58A9 cells.

Cancer Sci | May 2014 | vol. 105 | no. 5 | 535
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
Fig. S4. Effects of Met, fibroblast growth factor receptor (FGFR), and Src inhibitors on intracellular signaling pathways in diffuse-type gastric carcinoma (DGC) cell lines.

Fig. S5. Effect of saracatinib on proliferation of intestinal-type gastric carcinoma cell lines.

Table S1. List of cell lines used in this study.